

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



14th January, 2016

To
DCS-CRD
The Secretary
Bombay Stock Exchange
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To,
**National Stock Exchange of India
Limited**
“Exchange Plaza”,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051

**Sub: Un-audited Financial Results for the Quarter and nine months ended on 31st
December, 2015**

Scrip Code: 532637
Symbol: MANGALAM

Dear Sir,


In terms of Reg 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Unaudited Financial Results for the quarter & nine months ended 31st December, 2015 in the prescribed form which have been taken on record by the Board of Directors of the Company at its meeting held on 14th January, 2016 at Mumbai along with the Limited Review Report of the said period.

Further please note that the company has made necessary arrangement to publish the same in the newspaper as required under the Listing Agreement.

Kindly take the same in your records.

Thanking You,

Yours faithfully,
For Mangalam Drugs & Organics Ltd


Govardhan M Dhoot
Managing Director
DIN: 01240086



Works: at Vapi (Gujarat) India • E-Mail : contactus@mangalamdrugs.com • Website : <http://www.mangalamdrugs.com>

Un- Audited Financial Results(Provisional) for the Quarter and Nine Month ended 31st December 2015 approved and taken on record by the Board at their meeting dated 14th January,2016

Sr. No.	Particulars	(Rs. in Lacs)					
		Unaudited			Unaudited		Audited
		Quarter ended			NINE MONTH ENDED		Year Ended
		3 months ended	3 months ended	Corresponding 3 months ended in the previous period	figures for Current period ended	figures for the previous period ended	Previous accounting year ended
		31.12.15	30.09.15	31.12.14	31.12.15	31.12.14	31.03.15
PART I - STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER,2015							
1	Sales/Income from operation(Net of Excise duty)	8235.43	7255.60	6078.34	22447.12	14019.08	22058.39
2	Other Operating Income	0.00	0.00	216.26	2.72	488.97	7.47
3	Total Net Income from Operation	8235.43	7255.60	6294.60	22449.84	14508.05	22065.86
4	Expenditure						
	(a) Increase / decrease in stock in trade & work in progress	733.98	(1075.92)	(346.45)	409.82	552.26	(745.54)
	(b) Consumption of raw materials	5416.92	5930.01	4941.79	15723.65	9406.14	16324.04
	(c) Employee Benefits	360.72	359.17	292.31	1024.64	820.58	1095.20
	(d) Depreciation	114.98	109.45	100.27	332.68	300.80	415.40
	(e) Other expenditure	834.54	1241.70	906.45	2956.47	2292.67	3352.68
	(f) Total	7461.14	6564.41	5894.37	20447.26	13372.45	20441.78
5	Profit(+)/Loss(-) from operations before Other income,Finance cost and Exceptional Items(3-4)	774.29	691.19	400.23	2002.58	1135.60	1624.08
6	Other income	1.51	2.37	0.00	74.43	4.88	5.17
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	775.80	693.56	400.23	2077.01	1140.48	1629.25
8	Finance Cost	196.12	223.64	270.75	652.15	815.74	1028.37
9	Profit(+)/Loss(-) from ordinary activities after Finance cost but before Exceptional Items(7-8)	579.68	469.92	129.48	1424.86	324.74	600.88
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	579.68	469.92	129.48	1424.86	324.74	600.88
12	Tax Expenses(incl Deferred Tax)	200.00	105.00	45.00	375.00	60.00	(13.24)
13	Net Profit(+)/Loss(-) after Tax (11-12)	379.68	364.92	84.48	1049.86	264.74	614.12
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	379.68	364.92	84.48	1049.86	264.74	614.12
16	Paid up Equity Share Capital (face value Rs.10/-each)	1437.82	1317.82	1317.82	1437.82	1317.82	1317.82
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	0.00	0.00	0.00	1618.59
18 (i)	Earning per share (EPS) (before extraordinary items) (of ` 10/- each) (not annualised):						
	(a) Basic	2.64	2.77	0.64	7.30	2.01	4.66
	(b) Diluted	2.40	2.30	0.64	6.63	2.01	4.66
18 (ii)	Earning per share (EPS) (before extraordinary items) (of ` 10/- each) (not annualised):						
	(a) Basic	2.64	2.77	0.64	7.30	2.01	4.66
	(b) Diluted	2.40	2.30	0.64	6.63	2.01	4.66




A PART II - PARTICULARS OF SHAREHOLDING						
1	Non Promoters Shareholding					
	- Number of shares	7793511	7619615	7628115	7793511	7628115
	- Percentage of shareholding	54.20	57.82	57.88	54.20	57.88
2	Promoters and Promoter group Shareholding					
	a) Pledged/ Encumbered					
	Number of Shares	4050133	4050133	5491228	4050133	5491228
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	61.51	72.86	98.94	61.51	98.94
	Percentage of Shares (as a % of the total share capital of the company)	28.17	30.73	41.67	28.17	41.67
	b) Non-encumbered					
	Number of Shares	2534604	1508500	58905	2534604	58905
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	38.49	27.14	1.06	38.49	1.06
	Percentage of Shares (as a % of the total share capital of the company)	17.63	11.45	0.45	17.63	0.45
B	INVESTOR COMPLAINTS	3 Months ended 31.12.15				
	Pending at the Beginning of the Quarter		Nil			
	Received during the Quarter		Nil			
	Disposed of during the Quarter		Nil			
	Remaining unresolved at the end of the Quarter		Nil			

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 14th January, 2016
- The above results have been subjected to limited review by Statutory Auditors.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk Drugs" the disclosure requirements of Accounting Standard (AS-17) "Segment Reporting" is not applicable.
- 12,00,000 Equity Shares are allotted on 16/11/2015 pursuant to conversion of 12,00,000 share warrants which were allotted on 23/09/2015.
- While calculating diluted EPS outstanding 14,50,000 convertible share warrants issued on Preferential basis is considered.
- The CEO & CFO have certified that the Unaudited Financial Results for the Quarter and Nine Months Ended 31st December 2015 do not contain any false or misleading statement or figures and do not omit any material facts which may make the statements or figures contained therein misleading.
- Previous year figure are regrouped wherever necessary.

Place: Mumbai
Date: 14.01.2016



Milwani Associates
Chartered Accountants

(R. K. Milwani)
(Proprietor)

M.N. 036099
F.R.N. 106405W

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd.

(Shri. Govardhan M. Dhoot)
Chairman & Managing Director





18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel : 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

Limited Review Report

Review Report to
The Board of Directors
Mangalam Drugs & Organics Limited


We have reviewed the accompanying statement of unaudited financial results of Mangalam **Drugs & Organics Limited** for the period ended **31st December, 2015**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place of signature: Mumbai

Date: 14th January, 2016



For Milwani Associates.

Chartered Accountants

For Milwani Associates

Chartered Accountants

(R. K. Milwani)

(Proprietor)

RAKESH K MILWANI

Proprietor

Membership Number. 36099

Firm Reg No. 106405W